Press Releases Gain Therapeutics, Inc.

Equities

GANX

US36269B1052

Delayed Nasdaq Other stock markets 09:39:12 2024-06-12 am EDT			5-day change	1st Jan Change
2.41 ^USD	-0.82%		-3.60%	-26.19%

May. 14	Gain Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024	May. 30	GL
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update	May. 14	AQ
Gain Therapeutics Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease	Apr. 25	AQ
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease	Apr. 24	GL
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer	Apr. 08	GL
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer	Apr. 01	GL
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update	Mar. 26	GL
Gain Therapeutics to Present at Public Ventures Discovery Day	Mar. 15	GL
Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease	Mar. 05	GL
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease	Feb. 27	GL
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease	Feb. 27	AQ
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	Feb. 22	AQ
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight	Feb. 14	GL
UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease	Feb. 06	GL
Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease	Feb. 06	AQ
Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update	Jan. 31	GL
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024	Jan. 02	GL
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024	Jan. 02	AQ
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research	Dec. 04	GL
Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research	Dec. 04	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Gain Therapeutics, Inc.

Equities

GANX

US36269B1052

Press Releases

Filters